## Low Biological Activity of Helicobacter pylori Lipopolysaccharide

ANNA MUOTIALA,<sup>1</sup> ILKKA M. HELANDER,<sup>1</sup> LIISA PYHÄLÄ,<sup>2</sup> TIMO U. KOSUNEN,<sup>3</sup> and ANTHONY P. MORAN<sup>3</sup><sup>†\*</sup>

Department of Bacteriology and Molecular Biology Program<sup>1</sup> and Laboratory Animal Unit,<sup>2</sup> National Public Health Institute, SF-00300 Helsinki, and Department of Bacteriology and Immunology, University of Helsinki, SF-00290 Helsinki,<sup>3</sup> Finland

Received 25 September 1991/Accepted 29 January 1992

Lipopolysaccharide from the gastroduodenal pathogen *Helicobacter pylori* was tested for its ability to induce mitogenicity in mouse spleen cells, pyrogenicity in rabbits, and toxic lethality in galactosamine-sensitized mice. Compared with those for enterobacterial lipopolysaccharide, mitogenicity and pyrogenicity were a thousand-fold lower and lethal toxicity was 500-fold lower. We suggest that the phosphorylation pattern and acylation in lipid A are responsible for the low biological activity.

Extensive investigations worldwide have shown that Helicobacter pylori (formerly Campylobacter pylori) is the causal agent of active chronic gastritis and that a strong association between it and duodenal ulcers exists (16). Like the cell envelope of all other gram-negative bacteria, that of H. pylori contains lipopolysaccharide (LPS). In general, LPS is composed of a poly(oligo)saccharide and a lipid component termed lipid A (18, 20). It has been established that lipid A is essential for the endotoxic effects of gramnegative bacteria in vitro and in vivo (4, 7, 11, 20). Biologically active lipid A has a rather conservative structure which is characterized by a  $\beta(1\rightarrow 6)$ -linked (gluco-configured) D-hexosamine disaccharide backbone with phosphate groups at positions 1 and 4' and carrying (R)-3-hydroxy- and (R)-3-acyloxyacyl residues at positions 2, 3, 2', and 3' (14, 18, 20); e.g., lipid A of Escherichia coli and Salmonella enterica serovar Minnesota has this structure. In order to enhance our knowledge of the biology of H. pylori and its surface structures, we chemically characterized the lowmolecular-weight rough-form LPS of three H. pylori strains in a previous study (13). The results suggested that H. pylori lipid A, in addition to containing uncommonly long 3-hydroxy fatty acids (i.e., 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic), has as its backbone a D-glucosamine disaccharide which carries a phosphate group at position 1 but which is not phosphorylated at position 4'.

Studies with chemically defined synthetic analogs and partial structures of *E. coli* and *Salmonella* species lipid A have provided clear evidence that slight modifications to lipid A architecture (e.g., the loss of one constituent from the molecule or a different distribution of constituents) result in a significant reduction in biological activity (18, 20). Our chemical characterization of *H. pylori* LPS (13) suggested, therefore, that it would be less biologically active than enterobacterial LPS. To test this hypothesis, we investigated the ability of *H. pylori* LPS to induce a well-documented in vitro biological effect of endotoxin, B-lymphocyte mitogenicity, and two classical in vivo endotoxic effects, lethality in mice and pyrogenicity in rabbits.

*H. pylori* NCTC 11637, obtained from the National Collection of Type Cultures (Public Health Laboratory Service,

London, England), was used throughout our investigations. NCTC 11637 was chosen because it is a well-characterized strain, and although it has been extensively passaged in vitro, changes that occur during passaging affect the O side chain (13) and would be unlikely to modify lipid A structure, as alterations in this conservative moiety of LPS would influence the viability of the organism (18, 20). The strain was grown on blood agar (Trypticase soy agar [Difco, Detroit, Mich.], 6% horse blood) supplemented with 10% IsoVitaleX (BBL, Cockeysville, Md.) which was incubated in an atmosphere of 5%  $O_2,\,10\%$   $CO_2,\,and\,85\%$   $N_2$  at 37°C for 48 h. LPS was extracted from NCTC 11637 by the hot phenol-water technique (24) after pretreatment of bacteria with pronase (Calbiochem, Los Angeles, Calif.) and was purified by treatment with RNase A (Sigma Chemical Co., St. Louis, Mo.), DNase II (Sigma), and proteinase K (Sigma) and by subsequent ultracentrifugation as described previously (13). For comparison, LPS of S. enterica serovar Typhimurium SH2183 (22) and that of mutant strain his-515 (15) (LPS chemotype Ra) were used. These strains were cultivated on L agar (21). Serovar Typhimurium SH2183 LPS was extracted as described for H. pylori LPS but without pronase pretreatment, whereas serovar Typhimurium his-515 LPS was extracted by the phenol-chloroformpetroleum ether method (5).

The mitogenicity of LPS preparations was determined in  $(CBA \times C57BL/6)F_1$  mouse spleen cultures as described previously (6). Briefly, single-cell suspensions were cultured in RPMI 1640 (GIBCO, Paisley, Scotland) supplemented with 1 mM L-glutamine, 10% fetal bovine serum (GIBCO), and antibiotics (penicillin G, 50 U/ml; streptomycin, 50  $\mu$ g/ml) in round-bottom microtiter plates (Nunc, Roskilde, Denmark) to a final concentration of  $3 \times 10^5$  cells per well. Triplicate cultures were incubated without or with mitogens (concanavalin A [Sigma], 0.5  $\mu$ g per well; LPS, 0.001 to 10  $\mu$ g per well in tenfold dilutions) at 37°C for 48 h in a  $CO_2$ -enriched atmosphere (5%  $CO_2$ -95% air). After incubation, 0.5 µCi of [methyl-3H]thymidine (Amersham International, Amersham, England; 25 Ci/mmol) in 20 µl of RPMI 1640 was added to each well and incubation was continued for a further 18 h. Cultures were harvested with a Nunc cell harvester, and incorporated <sup>3</sup>H was measured by conventional liquid scintillation counting.

In addition, the lethal toxicity of LPS was determined for D-galactosamine-sensitized mice (2). Groups of five female  $(CBA \times C57BL/6)F_1$  mice aged 10 to 11 weeks and weighing

<sup>\*</sup> Corresponding author.

<sup>†</sup> Present address: Department of Microbiology, University College Galway, Galway, Ireland.

 TABLE 1. Stimulation of the [methyl-<sup>3</sup>H]thymidine uptake

 by mouse spleen cells by H. pylori and S. enterica

 serovar Typhimurium LPS<sup>a</sup>

Concn (µg/well) of LPS	Level of stimulation <sup>b</sup>		
	H. pylori NCTC 11637	S. enterica serovar Typhimurium	
		his-515	SH2183
0.001	544 ± 310	$1,302 \pm 88^*$	2,057 ± 785*
0.01	$1,077 \pm 180$	$10,736 \pm 1,380^{***}$	11,099 ± 1,230***
0.1	$1,792 \pm 159$	$24,371 \pm 505^{***}$	$25,661 \pm 3,648^{***}$
1	$4,331 \pm 315$	$30,187 \pm 472^{***}$	$25,833 \pm 8,281^{***}$
10	$14,149 \pm 1,850$	$21,621 \pm 2,004^{**}$	$26,182 \pm 1,726^{**}$

<sup>a</sup> Single-cell suspensions were cultured to a concentration of  $3 \times 10^5$  spleen cells per well. Values for unstimulated cultures and cultures stimulated with concanavalin A (0.5 µg per well) were  $320 \pm 168$  and  $47,157 \pm 1,192$ , respectively (mean count per minute  $\pm$  standard deviation).

<sup>b</sup> Mean counts per minute  $\pm$  standard deviation. Values include significance (\*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001) of the difference between stimulation with Salmonella species LPS and that with H. pylori LPS as determined by Student's t test.

20 to 23 g were used in tests. *H. pylori* NCTC 11637 LPS was injected intravenously as indicated previously (2) for roughform LPS. *S. enterica* serovar Typhimurium *his-515* LPS (chemotype Ra) was used as a positive control. Within 1 h of an intraperitoneal injection of galactosamine (Sigma; 12.5 mg per mouse) in 400  $\mu$ l of endotoxin-free water, the mice received LPS (0.0001 to 10  $\mu$ g per mouse in tenfold dilutions) in 200  $\mu$ l of sterile saline intravenously. Control mice received only galactosamine. Deaths were recorded at 24 h, and values for the 50% lethal dose were calculated according to the method of Reed and Muench (17).

Finally, pyrogenicity was tested in chinchilla rabbits which were bred, reared, and maintained in a conventional environment in air-conditioned rooms at  $21.0 \pm 2^{\circ}C$  with a relative humidity of 45 to 65% and a photoperiod of 14 h/day. Rabbits were housed individually, fed a commercial diet (K1; Ewos AB, Wadstena, Sweden) (120 g/day) and given water ad libitum. The pyrogen assay was performed according to the European Pharmacopoeia (1) with rabbits weighing 3.3 to 4 kg in groups of three to five. Rabbits were pretrained and tested with pyrogen-free saline in preliminary assays. Rectal temperature was monitored with indwelling thermistor probes (Ellab A/S, Copenhagen, Denmark) and a strip chart recorder. The minimal pyrogenic doses after 3 h from injection (MPD-3) (19) were titrated by using appropriate dilutions (0.05 to 5  $\mu$ g per kg of body weight in 1 ml for Helicobacter species LPS; 0.005 to 0.5 µg per kg in 1 ml for Salmonella species LPS).

The mitogenicity of LPS of *H. pylori* NCTC 11637 and those of LPSs of *S. enterica* serovar Typhimurium *his-515* and SH2183 are shown in Table 1. Within the concentration range tested, the LPSs of both serovar Typhimurium strains brought about nearly a hundredfold stimulation compared with unstimulated cultures. For *H. pylori* LPS, the strongest stimulation was 44-fold, at a concentration of 10  $\mu$ g of LPS per 0.2 ml of culture. This stimulatory effect was of a magnitude similar to those obtained with 0.01  $\mu$ g of serovar Typhimurium LPS per 0.2 ml of culture. The LPS of *H. pylori* NCTC 11637, therefore, exhibited mitogenic activity about a thousand times lower than those of serovar Typhimurium strains.

In the lethal toxicity test with D-galactosamine-sensitized mice, *H. pylori* LPS also exhibited low activity. The 50% lethal doses were 2.1 and 0.0037  $\mu$ g for LPS of NCTC 11637

and *his-515*, respectively, demonstrating a 500-fold difference in the lethalities of these LPSs. In addition, the pyrogenicity of *H. pylori* LPS in rabbits was low; its MPD-3 was 1.2  $\mu$ g of LPS per kg. *S. enterica* serovar Typhimurium SH2183 and *his-515* gave MPD-3s on the order of 1 ng. Accordingly, the pyrogenicity of *H. pylori* LPS was a thousandfold lower than those of the serovar Typhimurium strains.

Our results show that *H. pylori* LPS possesses low mitogenic and pyrogenic activities and low lethal toxicity, suggesting that the primary role of lipid A should not be considered endotoxicity alone, but that it can be to provide a functional macromolecular matrix through which the bacterium interacts with its environment. It is interesting that *Bacteroides fragilis* LPS, which also expresses low pyrogenicity and toxicity, has a  $\beta(1\rightarrow 6)$ -linked D-glucosamine disaccharide backbone phosphorylated at position 1 only, with long 3-hydroxy fatty acids whose average chain length is 16 carbon atoms (23).

Studies on synthetic Salmonella species- and E. coli-like lipid A partial structures and analogs have shown that phosphorylation patterns (3, 7, 8, 10, 11), fatty acid composition (9, 12), and the presence of acyloxyacyl groups (19) are important for the full expression of a range of biological activities. As synthetic lipid A partial structures that are monophosphorylated and lipid A analogs that carry acyl chains of increased length have been shown to exhibit decreased biological activity (7, 11, 12), it is likely that the phosphorylation pattern and acylation in *H. pylori* lipid A (13), probably in a combined form, are the basis for the low biological activity of *H. pylori* LPS.

We thank L. Liesirova and P. Riikonen for assistance during biological testing and P. H. Mäkelä for critically reading the manuscript.

This work was supported financially by the Sigrid Jusélius Foundation, the Yrjö Jahnsson Foundation, and the University of Helsinki.

## REFERENCES

- 1. European Pharmacopoeia: Part 1, 2nd ed., V.2.1.4. 1986. Maisonneuve S.A., Sainte-Ruffine, France.
- Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 75:5939–5943.
- 3. Galanos, C., V. Lehmann, O. Lüderitz, E. T. Rietschel, O. Westphal, H. Brade, L. Brade, M. A. Freudenberg, T. Hansen-Hagge, T. Lüderitz, G. McKenzie, U. Schade, W. Strittmatter, K.-I. Tanamoto, U. Zähringer, M. Imoto, H. Yoshimura, M. Yamamoto, T. Shimamoto, S. Kusumoto, and T. Shiba. 1984. Endotoxic properties of chemically synthesized lipid A part structures. Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and lipid A. Eur. J. Biochem. 140:221-227.
- Galanos, C., O. Lüderitz, E. T. Rietschel, O. Westphal, H. Brade, L. Brade, M. Freudenberg, U. Schade, M. Imoto, H. Yoshimura, S. Kusumoto, and T. Shiba. 1985. Synthetic and natural *Escherichia coli* free lipid A expresses identical endotoxic activities. Eur. J. Biochem. 148:1–5.
- Galanos, C., O. Lüderitz, and O. Westphal. 1969. A new method for the extraction of R lipopolysaccharides. Eur. J. Biochem. 9:245-249.
- 6. Helander, I., K. Saukkonen, E. Hakalehto, and M. Vaara. 1984. Biological activities of lipopolysaccharides from *Pectinatus cerevisiophilus*. FEMS Microbiol. Lett. 24:39-42.
- Homma, J. Y., M. Matsuura, S. Kanegasaki, Y. Kawakubo, Y. Kojima, N. Shibukawa, Y. Kumazawa, A. Yamamoto, K.-i. Tanamoto, T. Yasuda, M. Imoto, H. Yoshimura, S. Kusumoto, and T. Shiba. 1985. Structural requirements of lipid A responsible for the functions: a study with chemically synthesized lipid

A and its analogues. J. Biochem. (Tokyo) 98:395-406.

- Kanegasaki, S., Y. Kojima, M. Matsuura, J. Y. Homma, A. Yamamoto, Y. Kumazawa, K.-I. Tanamoto, T. Yasuda, T. Tsumita, M. Imoto, H. Yoshimura, M. Yamamoto, T. Shimamoto, S. Kusumoto, and T. Shiba. 1984. Biological activities of analogues of lipid A based chemically on the revised structural model. Comparison of mediator-inducing, immunomodulating and endotoxic activities. Eur. J. Biochem. 143:237-242.
- Kanegasaki, S., K.-I. Tanamoto, T. Yasuda, J. Y. Homma, M. Matsuura, M. Nakatsuka, Y. Kumazawa, A. Yamamoto, T. Shiba, S. Kusumoto, M. Imoto, H. Yoshimura, and T. Shimamoto. 1986. Structure-activity relationship of lipid A: comparison of biological activities of natural and synthetic lipid A's with different fatty acid compositions. J. Biochem. (Tokyo) 99:1203– 1210.
- Kotani, S., H. Takada, M. Tsuijmoto, T. Ogawa, K. Harada, Y. Mori, A. Kawasaki, A. Tanaka, S. Nagao, S. Tanaka, T. Shiba, S. Kusumoto, M. Imoto, H. Yoshimura, M. Yamamoto, and T. Shimamoto. 1984. Immunobiologically active lipid A analogs synthesized according to a revised structural model of natural lipid A. Infect. Immun. 45:293-296.
- 11. Kotani, S., H. Takada, M. Tsujimoto, T. Ogawa, I. Takahashi, T. Ikeda, K. Otsuka, H. Shimauchi, N. Kasai, J. Mashimo, S. Nagao, A. Tanaka, S. Tanaka, K. Harada, K. Nagaki, H. Kitamura, T. Shiba, S. Kusumoto, M. Imoto, and H. Yoshimura. 1985. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an *Escherichia coli* Re-mutant. Infect. Immun. 49:225-237.
- Kumazawa, Y., M. Nakatsuka, H. Takimoto, T. Furuya, T. Nagumo, A. Yamamoto, J. Y. Homma, K. Inada, M. Yoshida, M. Kiso, and A. Hasegawa. 1988. Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity. Infect. Immun. 56:149-155.
- Moran, A. P., I. M. Helander, and T. U. Kosunen. 1992. Compositional analysis of *Helicobacter pylori* rough-form lipopolysaccharides. J. Bacteriol. 174:1370–1377.
- 14. Moran, A. P., U. Zähringer, U. Seydel, D. Scholz, P. Stütz, and E. T. Rietschel. 1991. Structural analysis of the lipid A component of *Campylobacter jejuni* CCUG 10936 (serotype O:2) lipopolysaccharide. Description of a lipid A containing a hybrid

backbone of 2-amino-2-deoxy-D-glucose and 2,3-diamino-2,3-dideoxy-D-glucose. Eur. J. Biochem. **198:**459–469.

- Nikaido, H., M. Levinthal, K. Nikaido, and K. Nakane. 1967. Extended deletions in the histidine-rough-B region of the Salmonella chromosome. Proc. Natl. Acad. Sci. USA 57:1825– 1832.
- Rautelin, H., and T. U. Kosunen. 1991. Helicobacter pylori and associated gastroduodenal diseases. APMIS 99:677–695.
- Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493–497.
- Rietschel, E. T., L. Brade, O. Holst, V. A. Kulshin, B. Lindner, A. P. Moran, U. F. Schade, U. Zähringer, and H. Brade. 1990. Molecular structure of bacterial endotoxin in relation to bioactivity, p. 15-32. *In A. Nowotny, J. J. Spitzer, and E. J. Ziegler* (ed.), Endotoxin research series, vol. 1. Cellular and molecular aspects of endotoxin reactions. Elsevier Science Publishers B.V., Amsterdam.
- Rietschel, E. T., L. Brade, U. Schade, C. Galanos, M. Freudenberg, O. Lüderitz, S. Kusumoto, and T. Shiba. 1987. Endotoxic properties of synthetic pentaacyl lipid A Ib and a structural isomer. Eur. J. Biochem. 169:27–31.
- Rietschel, E. T., L. Brade, U. Schade, U. Seydel, U. Zähringer, B. Lindner, A. P. Moran, V. A. Kulshin, Y. Haishima, O. Holst, E. Röhrscheidt-Andrzeweski, A.-J. Ulmer, H. D. Flad, and H. Brade. 1990. Chemical structure and biological activity of lipopolysaccharides, p. 5–18. *In* J. D. Baumgartner, T. Calandra, and J. Carlet (ed.), Endotoxin from pathophysiology to therapeutic approaches. Flammarion Médecine-Sciences, Paris.
- Sukupolvi, S., M. Vaara, I. M. Helander, P. Viljanen, and P. H. Mäkelä. 1984. New Salmonella typhimurium mutants with altered outer membrane permeability. J. Bacteriol. 159:704-712.
- 22. Valtonen, V. V. 1970. Mouse virulence of *Salmonella* strains: the effect of different smooth-type O side-chains. J. Gen. Microbiol. **64**:255-268.
- Weintraub, A., U. Zähringer, H.-W. Wollenweber, U. Seydel, and E. T. Rietschel. 1989. Structural characterization of the lipid A component of *Bacteroides fragilis* strain NCTC 9343 lipopolysaccharide. Eur. J. Biochem. 183:425–431.
- 24. Westphal, O., O. Lüderitz, and F. Bister. 1952. Über die Extraktion von Bakterien mit Phenol/Wasser. Z. Naturforsch. Teil B 7:148–155.